We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum Vasopressin Levels and Severe Hemorrhagic Shock

This study has been withdrawn prior to enrollment.
(Study closed without enrollment .)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01676454
First Posted: August 31, 2012
Last Update Posted: January 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Julie Dunn, M.D., Poudre Valley Health System
  Purpose
The purpose of this study is to determine if vasopressin is used up by the body during traumatic shock (severe low blood pressure due to trauma).

Condition
Injury

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Determination of Serum Vasopressin Levels and Correlation With Life-threatening Complications in Adults With Severe Hemorrhagic Shock.

Resource links provided by NLM:


Further study details as provided by Julie Dunn, M.D., Poudre Valley Health System:

Primary Outcome Measures:
  • Serum vasopressin levels. [ Time Frame: 24 hours. ]
    6 mL's per blood draw for 5 timepoints=30 mL's total blood drawn.


Enrollment: 0
Study Start Date: November 2012
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Vasopressin levels.

Cohort will consist of subjects with a minor injury or injuries defined as:

  1. no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and admission;
  2. no blood transfusion requirement;
  3. base deficit < 5 mEq/L;
  4. no requirement for mechanical ventilation other than transiently during orthopedic surgery.

Detailed Description:

For humans suffering trauma and severe hemorrhagic shock, no randomized controlled studies of the effect of exogenous vasopressin use exist, although case reports have suggested it may be of benefit. Even some moribund patients with "irreversible" shock survived severe hemorrhagic shock after administration of vasopressin. This suggests that at least some patients suffering severe trauma could benefit from AAVP administration. Recently, many clinicians and notable research consortiums have suggested that AVP shows promise for human resuscitation and have called for further human studies.

This is a prospective, single-center observational study designed to evaluate (1) whether vasopressin is depleted in severe, but not minor, trauma; and (2) the degree to which endogenous vasopressin levels predict the occurrence of ARDS, sepsis, or death. To test the first hypothesis, serum vasopressin levels (continuous independent variable) will be assessed at enrollment (time 0), 6, 12, 18, and 24 hours later, and correlated with the two levels of trauma (categorical dependent variable). To test the second hypothesis, serum vasopressin levels (now a continuous dependent variable) will be correlated with each of three outcomes-death, ARDS, and sepsis.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients admitted to Medical Center of the Rockies with minor injuries.
Criteria

Inclusion Criteria:

Patients with a minor injury or injuries, defined as:

  1. no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and admission;
  2. no blood transfusion requirement;
  3. base deficit < 5 mEq/L;
  4. no requirement for mechanical ventilation other than transiently during orthopedic surgery.

Exclusion Criteria:

  1. Pregnancy
  2. corticosteroid use,
  3. prisoners, and/or
  4. head trauma as determined by computed tomography (head trauma may itself induce diabetes insipidus, a marker of pituitary damage and vasopressin deficiency), and/or
  5. evidence of spinal cord injury (another cause of vasodilatory shock).

Patients will also be excluded if pre-hospital provider information cannot be obtained, or indicates that the trauma occurred more than one 1 hour prior to emergency department admission.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01676454


Locations
United States, Colorado
Medical Center of the Rockies
Loveland, Colorado, United States, 80538
Sponsors and Collaborators
Poudre Valley Health System
Investigators
Principal Investigator: Julie Dunn, M.D. Poudre Valley Health System
  More Information

Additional Information:
Responsible Party: Julie Dunn, M.D., Principal Investigator, Poudre Valley Health System
ClinicalTrials.gov Identifier: NCT01676454     History of Changes
Other Study ID Numbers: Vasopressin Study
First Submitted: August 21, 2012
First Posted: August 31, 2012
Last Update Posted: January 4, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Julie Dunn, M.D., Poudre Valley Health System:
Vasopressin
Trauma
Injury

Additional relevant MeSH terms:
Shock, Hemorrhagic
Hemorrhage
Pathologic Processes
Shock
Vasopressins
Arginine Vasopressin
Hemostatics
Coagulants
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs